VTU Group’s Post

🌟 Pioneering the Future of Drug Discovery: Insights from Bristol Myers Squibb at RECON 🌟 📊 Today at RECON, Dr. Remco Loos from Bristol Myers Squibb delivered a groundbreaking presentation on “Prediction-Driven Drug Discovery.” 🧬 Key Highlights: 1️⃣ Dr. Loos explored the evolving landscapes of data in drug discovery, highlighting how vast data resources are transforming the way pharmaceuticals are developed. 2️⃣ He provided an in-depth look at the opportunities for creating more informed and effective drug discovery programs through advanced data analysis. 𝗙𝗼𝗰𝘂𝘀𝗶𝗻𝗴 𝗼𝗻 𝗗𝗮𝘁𝗮 𝗠𝗶𝗻𝗶𝗻𝗴: - The talk delved into the strategic mining of data to design better-targeted and more efficient drug discovery programs. - Dr. Loos emphasized how leveraging big data and predictive analytics can significantly enhance the success rates and efficiency of drug discovery processes. 🌐 His presentation painted a picture of a future where data-driven insights lead the way in creating breakthrough treatments. 🔗 Stay tuned for more exciting developments and insights from the RECON Conference! #RECONConference #BristolMyersSquibb #DrugDiscovery #DataScience #HealthcareInnovation

FAIR isn't just about accessibility—it's about empowerment. Making data and analytics Findable, Accessible, Interoperable, and Reusable (FAIR) is important beyond academia, it’s also crucial in the biopharmaceutical industry. FAIR provides a foundation to advance knowledge within organizations and democratize access to insights. Dr. Jack DiGiovanna, CSO at Velsera, shared his insights on how embracing FAIR principles for data and analytics can help cross the chasm between basic research and novel therapeutics becoming standard of care during Bio-IT World 2024 earlier this month. FAIRness isn't without its challenges, especially when the principles are applied also to analytics. Time remains a powerful challenger, especially as the drug development life cycle with the standard turnover or reorganizations within the industry. Jack highlighted the importance of global standards, how they have been successfully applied, and where analytical platforms can serve as the bedrock of this transformative movement. Jack discussed how current platforms, especially in the NIH space, are paving the way for FAIR data and analysis; discussed key areas for future development; and highlighted where continuing support will be most impactful. Build a future where data isn't just collected—it's connected, shared, and utilized for meaningful impact with Velsera today! Make your analytics sharable, interpretable, and able to be validated. Contact us to learn more: https://lnkd.in/df3EP_2g #FAIRData #ResearchImpact #DataScience #Innovation

Only a little over two weeks until our next DataHop event, this time in the U.S. - Boston!! There will be onsite workshops around GenAI topics and enablement for your data streams, impactful insights with use cases from customers and of course opportunities to network with the broader KNIME community. Join us! (registration link below) #datainaction #genai #dataanalysis

We look back on a successful Reuters Events Pharma Conference! Next to co-hosting on stage, our International Life Sciences team participated in discussions on cutting-edge technologies and exchanged their knowledge with industry experts and thought leaders. Throughout the event there was one particular topic that took center stage: GenAI. The consensus was clear that GenAI is not just a trend; it's a permanent fixture in our technological landscape. Curious to learn more about unleashing innovation in the pharmaceutical industry? Dive into Eraneos’ customer stories or connect with our International Life Sciences team to guide you through the digital transformation of your commercial operations. #Eraneos #GenAI https://okt.to/Vbn1Yp

Exciting developments in data science are shaping the future of biopharma and biotech R&D! The recent DISRUPT-DS industry roundtable, featuring leaders from major biopharma companies, highlighted how data science is driving innovation and collaborating across the industry. By sharing insights and best practices, this forum is paving the way for more effective drug discovery and development. It’s inspiring to see how data-driven approaches are transforming the healthcare landscape. Learn more about the roundtable and how biopharma companies are using data science in R&D: https://lnkd.in/gngcj3US

The Parexel team will be in London this month for the 5th Annual Pharma AI Summit! Our Chief Data and Digital Officer, Stephen Pyke will serve as a day one chairman and later in the day moderate a conversation on Getting to End-to-End AI-Enabled Clinical Trials Faster. Martin Keywood, Scientific Data Technology Senior Director at Parexel, will also be speaking in a presentation on Realizing Value in AI in Drug Development. We're excited to join some of the brightest minds in pharmaceutical technology innovation as we continue to explore the enormous potential artificial intelligence provide in clinical research and the improvement of patient care. Comment below if I can connect you with an expert from my team while you're there! More information: #PharmaAI #PharmaInnovation #AISummit #PharmaAI2024

The Parexel team will be in London this month for the 5th Annual Pharma AI Summit! Our Chief Data and Digital Officer, Stephen Pyke will serve as a day one chairman and later in the day moderate a conversation on Getting to End-to-End AI-Enabled Clinical Trials Faster. Martin Keywood, Scientific Data Technology Senior Director at Parexel, will also be speaking in a presentation on Realizing Value in AI in Drug Development. We're excited to join some of the brightest minds in pharmaceutical technology innovation as we continue to explore the enormous potential artificial intelligence provide in clinical research and the improvement of patient care. Comment below if I can connect you with an expert from my team while you're there! More information: #PharmaAI #PharmaInnovation #AISummit #PharmaAI2024

Count Down 4 days until PMWC 2024!  Join the discussion on Accelerating Drug Development Approvals Using RWE/D PMWC Track 2 AI& Data Sciences Silicon Valley January 25th (day 2), 2:00 - 3:00 pm  Panelists:  - Mika Newton, xCures (Chair) - Leo Russo, PhD, Pfizer - Eric Schadt, Pathos - Ashley Brenton, Ph.D., Optum - Nasha Fitter, Ciitizen 💡 Exploring Key Focus Areas: -Revolutionizing Clinical Trials: Harnessing Real-World Evidence/Data for Enhanced Drug Development. -Regulatory Navigation: Understanding and adapting to the evolving regulatory landscape. -Data Integrity and Quality: Prioritizing the reliability and accuracy of data in clinical studies. -Patient-Centric Approaches: Advancing drug development with a focus on patient needs. -Innovative Data Analysis: Utilizing cutting-edge techniques for insightful data interpretation. -Pharmaceutical Collaborations: Fostering partnerships for improved outcomes. -RWE/D Successes and Future Vision: Learning from success stories and predicting future trends. 🔬 This session is an essential platform for professionals in the pharmaceuticals, healthcare, and technology sectors. Don't miss this opportunity to delve into the future of drug development and gather valuable insights from leading industry experts! https://lnkd.in/gi_mHZdC Looking forward to seeing you all in a few days! PMWC - Precision Medicine World Conference #PMWC24 #precisionmedicine #drugdevelopment #realworldevidence #rwe #dataintegrity #PatientCentricApproaches #PharmaceuticalCollaborations #healthcaretechnology #ai #datasciences #clinicaltrials #dataquality #AcceleratingDrugDevelopment #RWEsuccess #DrugDevelopmentApprovals #realworlddata #pharma #biotech #lifesciences #healthcareindustry #medicalresearch #datasharing

🌟 Highlights from Day Three at BIO International Convention: 📢 Amgen CEO Bob Bradway on the ‘Innovation Reduction Act’ Bradway expressed concerns about the IRA's impact on biotech innovation, particularly its shortened timeframe for small molecules. He emphasized the need for better support for preventative therapies. 📢 Novo Nordisk’s BD Strategy: Opportunities Over Cash Novo Nordisk's John McDonald discussed leveraging their financial strength from semaglutide success. While there's no budget limit for BD, the focus is on quality opportunities and partnerships over large acquisitions. 📢 Roivant Sciences: No Rush to Sell Immunovant’s FcRn Candidate CEO Matt Gline highlighted Roivant’s strategic patience with Immunovant’s FcRn inhibitor, IMVT-1402, bolstered by strong financials from a prior Roche deal. Roivant is keen on exploring the asset’s potential before making any decisions. 📢 AI Experts Discuss Global Regulatory Considerations Chris Hart of Foley Hoag LLP and other experts discussed the fragmented US AI regulation versus the comprehensive EU approach. Challenges like AI data structuring and interoperability were emphasized, along with managing AI hallucinations through collaboration and benchmarking. #BIO24 #Innovation #Healthcare #Pharma #AI #Regulation #Amgen #NovoNordisk #RoivantSciences #BusinessDevelopment #ClinicalTrials #TechPolicy #Biotech #Strategy #PreventativeCare #Citeline #InflationReductionAct

At Capgemini, we're all about transforming data and research into real results, pushing pharma into the future while caring for humanity. That’s why we're thrilled to be part of BioTechX Europe 2024, showcasing our R&D, Clinical Development, GenAI, and pharma innovation capabilities and expertise. 🌟 What's BioTechX Europe? BioTechX Europe is the go-to event for diagnostics, precision medicine, and digital transformation in pharma and healthcare. This year, it's back in Basel, Europe’s pharma hub, on October 9 and 10, bringing together:  - 3,500+ attendees  - 400+ speakers  - 50+ start-ups The event is packed with networking opportunities and insights from top pharmaceutical and biotech companies, healthcare systems providers, start-ups and academic groups. If you want to know more, please visit: https://lnkd.in/dGcQqSQd Join us to explore the future of pharma and healthcare! 🚀 #BioTechX #PharmaInnovation #DigitalTransformation #ClinicalDevelopment #GenAI #Healthcare #Researchanddevelopment